242 related articles for article (PubMed ID: 26418700)
1. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
2. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
3. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.
Mannheimer B; Holm J; Koukel L; Bertilsson L; Osby U; Eliasson E
Eur J Clin Pharmacol; 2014 Jun; 70(6):695-9. PubMed ID: 24643635
[TBL] [Abstract][Full Text] [Related]
4. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
Haslemo T; Eliasson E; Jukić MM; Ingelman-Sundberg M; Molden E
Br J Clin Pharmacol; 2019 Jan; 85(1):194-201. PubMed ID: 30312494
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
8. Venlafaxine serum levels and CYP2D6 genotype.
Veefkind AH; Haffmans PM; Hoencamp E
Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
10. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
13. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
14. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Molden E; Waade RB; Hoff M; Haslemo T
Basic Clin Pharmacol Toxicol; 2016 Nov; 119(5):470-475. PubMed ID: 27145399
[TBL] [Abstract][Full Text] [Related]
15. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
Kneller LA; Hempel G
Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
[TBL] [Abstract][Full Text] [Related]
16. Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics.
Hinrichs JW; Loovers HM; Scholten B; van der Weide J
Eur J Clin Pharmacol; 2008 Oct; 64(10):979-86. PubMed ID: 18553077
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
